Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for endocrine and metabolic disorders [3] - The company is advancing a pipeline that includes canvuparatide for chronic hypoparathyroidism in Phase 2 development, MBX 1416 for post-bariatric hypoglycemia in Phase 1 development, and an obesity portfolio including MBX 4291 with an IND filing anticipated in Q2 2025 [3] Upcoming Events - Kent Hawryluk, President and CEO of MBX Biosciences, will present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, from 10:30 a.m. to 11:00 a.m. ET in Boston, MA [1] - The company will also participate in the Jefferies Biotech on the Beach Summit on March 12, 2025, with a format of 1x1 meetings in Miami Beach, FL [2] - Presentation webcasts will be accessible on the investors section of the MBX Biosciences website, with replays available approximately two hours after the events [2]
MBX Biosciences to Participate in March Investor Conferences